Taiwan has become the latest APAC region to approve the use of 2’-fucosyllactose (2’-FL) – a human milk oligosaccharide (HMO) – in nutrition products for infant and young children, with firms hopeful of further sector growth as more authorities permit the use of the ingredient.
You May Also Like

‘Possible opportunity’: ANZ infant nutrition firms gear up for US market entry amid formula shortage
INCJune 27, 2022

Beyond mimicking breastmilk: Why infant nutrition R&D should assess gut-brain axis and benefits into adulthood
INCMay 16, 2022

Study shows HMO levels in breast milk to aid next-gen formula development
INCApril 19, 2022